Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

RP-2

Generic Name: RP-2

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Phase 2

Recruiting

Posted: 2024/09/03

Sponsor:Replimune Inc.

ID:NCT06581406

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Phase 2

Active, not recruiting

Posted: 2023/02/17

Sponsor:Replimune Inc.

ID:NCT05733611

RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Phase 2

Recruiting

Posted: 2023/02/17

Sponsor:Replimune Inc.

ID:NCT05733598

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Replimune's RP1 Melanoma Therapy Nears FDA Decision with July PDUFA Date as Commercial Infrastructure Readies for Launch

7 days ago

Replimune's BLA for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma is proceeding on schedule with a PDUFA date of July 22, 2025, following completed manufacturing inspections and late cycle review.

Replimune's RP2 Advances in Clinical Trials for Melanoma and Liver Cancer

5 months ago

Replimune has initiated two clinical trials for RP2, an oncolytic immunotherapy, targeting metastatic uveal melanoma and hepatocellular carcinoma.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy